Sai Parenteral's Board approved an unsecured loan up to AUD 1.75 million to its Singapore subsidiary for downstream funding.
The loan, equivalent to INR 11.91 crore, is designated for Noumed Pharmaceuticals in Australia.
The board meeting was held on April 20, 2026, and lasted for 2 hours and 40 minutes.
This disclosure is a regulatory filing made under SEBI LODR Regulations.